Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

Cavalry Fund I LP

2. Date of Event Requiring Statement (MM/DD/YYYY) 12/14/2020

3. Issuer Name and Ticker or Trading Symbol

BLONDER TONGUE LABORATORIES INC [BDR]

(Last) (First) (Middle)

82 E. ALLENDALE RD.

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director ___X___ 10% Owner
_____ Officer (give title below) _____ Other (specify below)

(Street)

SADDLE RIVER, NJ 07458

(City) (State) (Zip)

5. If Amendment, Date Original Filed(MM/DD/YYYY)

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	1250000 ⁽¹⁾	D

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Warrants	12/15/2020 ⁽¹⁾	12/15/2023 ⁽¹⁾	Common Stock	625000 ⁽¹⁾	$1.25 ⁽¹⁾	D

Explanation of Responses:

(1)

Pursuant to that certain Securities Purchase Agreement, dated December 14, 2020, between Blonder Tongue Laboratories, Inc. (the "Company") and Cavalry Fund I LP (the "Reporting Person"), the Reporting Person purchased 1,250,000 shares of the Company's common stock ("Common Stock") and warrants to purchase 625,000 shares of Common Stock at an exercise price of $1.25 per share (the "Warrants"). The Warrants are exercisable at any time from December 15, 2020 until December 15, 2023 at 5:00 p.m., New York City time, subject to a beneficial ownership limitation of 4.99% of the Company's issued and outstanding Common Stock.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Cavalry Fund I LP 82 E. ALLENDALE RD. SADDLE RIVER, NJ 07458		X

Signatures
s/ Thomas Walsh, Manager of Cavalry Fund I Management LLC, General Partner of the Reporting Person		1/14/2021
^**Signature of Reporting Person		Date